Development of MicroRNA Therapeutics for Hepatocellular Carcinoma
Open Access
- 15 March 2013
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 3 (1), 170-191
- https://doi.org/10.3390/diagnostics3010170
Abstract
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. Treatment options for HCC are very limited, as it is often diagnosed at a late stage. Recent studies have demonstrated that microRNAs (miRNAs), a class of non-coding RNAs, are aberrantly expressed in HCC. Some of these were shown to be functionally involved in carcinogenesis and tumor progression, suggesting that miRNAs can serve as novel molecular targets for HCC therapy. Several promising studies have recently demonstrated the therapeutic potential of miRNAs in animal models and in reducing the viral load in hepatitis C patients. In this review, these advances and strategies for modulating miRNAs for in vivo therapeutic delivery and replacement therapy are discussed.This publication has 117 references indexed in Scilit:
- Role of miR-148a in Hepatitis B Associated Hepatocellular CarcinomaPLOS ONE, 2012
- Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic modelHepatology, 2012
- MicroRNA-99a Inhibits Hepatocellular Carcinoma Growth and Correlates with Prognosis of Patients with Hepatocellular CarcinomaJournal of Biological Chemistry, 2011
- MicroRNA Replacement Therapy for miR-145 and miR-33a Is Efficacious in a Model of Colon CarcinomaCancer Research, 2011
- Role of anti-oncomirs miR-143 and -145 in human colorectal tumorsCancer Gene Therapy, 2010
- A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interferenceNucleic Acids Research, 2009
- Elevated Expression of the miR-17–92 Polycistron and miR-21 in Hepadnavirus-Associated Hepatocellular Carcinoma Contributes to the Malignant PhenotypeThe American Journal of Pathology, 2008
- Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular CarcinomaCancer Research, 2007
- Fibroblast growth factor-4 and hepatocyte growth factor induce differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocytesWorld Journal of Gastroenterology, 2005
- Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancersProceedings of the National Academy of Sciences of the United States of America, 2004